SCHEMBL28639401

SCHEMBL28639401

NC(=O)OCc1ncc(Br)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
MAPK10 P53779 1/20 0.35
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34
CDK5 Q00535 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
PDK1 Q15118 1/20 0.34
PDK2 Q15119 1/20 0.34
PDK3 Q15120 1/20 0.34
PDK4 Q16654 1/20 0.34
NQO1 P15559 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29035492 0.76 LMNA (0.34) LMNANQO1
SCHEMBL29208120 0.76 SMN1; SMN2 (0.37) LMNASMN1; SMN2NQO1MAPTL3MBTL1
SCHEMBL29035247 0.75 HDAC6 (0.33) LMNA
SCHEMBL28457543 0.74 KDM4E (0.39) LMNASMN1; SMN2PDK1PDK2PDK3
SCHEMBL27779427 0.73 MAPK10 (0.34) SMN1; SMN2MAPK10CCNE1CDK2CDK5
SCHEMBL20508384 0.73 F2 (0.36) SMN1; SMN2NQO1CYP1A2CYP3A4MAPT
SCHEMBL21772786 0.72
SCHEMBL21571637 0.71 CHRM4 (0.38) FPR2FPR3
SCHEMBL28644238 0.70 LOXL2 (0.41) LMNASMN1; SMN2CCNE1CDK2CYP1A2
SCHEMBL12210734 0.70 SMN1; SMN2 (0.51) LMNASMN1; SMN2MAPK10CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 CN disclosed
CN-109311839-B Methylamine derivatives as lysyl oxidase inhibitors for the treatment of cancer 癌症研究协会皇家癌症医院 2021-11-02 CN disclosed